Neuroprotective peptides

• US 7,259,146 B2
• Filed: 05/23/2001
• Issued: 08/21/2007
• Est. Priority Date: 05/26/2000
• Status: Expired due to Fees

• Current Assignee: Ortho-McNeil Pharmaceutical Incorporated (Johnson & Johnson)
• Original Assignee: Ortho-McNeil Pharmaceutical Incorporated (Johnson & Johnson)
• Inventors: Farrell, Francis, Johnson, Dana, Renzi, Michael, Plata-Salaman, Carlos, Smith-Swintosky, Virginia, Jolliffe, Linda
• Primary Examiner(s): Weber; Jon
• Assistant Examiner(s): Mohamed; Abdel A.
• Application Number:
  US09/863,600
• Publication Number:
  US 20030130197A1
• Time in Patent Office: 2,281 Days
• Field of Search: 514/16, 514/15, 514/14, 514/13, 514/12, 530/300, 530/328, 530/327, 530/326, 530/325, 530/324, 530/345
• US Class Current: 514/8.3
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: C07K 14/505 Erythropoietin [EPO]

Abstract

Methods of treating diseases of the nervous system by administration of compositions having the neurological therapeutic activity of human erythropoietin are disclosed. These compositions include therapeutic agents such as peptides, peptide dimers, polypeptides, and proteins that have the full range of biological activity of human erythropoietin or only certain biological activities of erythropoietin. Improved therapeutic regimens where the erythropoietin is administered at concentrations below those required to stimulate hematopoiesis are also provided.

Claims

1. A method for promoting neurite outgrowth in a cell culture, comprising administering to said cell culture an effective amount of one or more monomeric peptides, selected from the group consisting of:

GGTYSCHFGPLTWVCKPQGG (SEQ ID NO;

8);

GGTASCHFGPLTWVCKPQGG (SEQ ID NO;

19);

GGTYSCHFAPLTWVCKPQGG (SEQ ID NO;

20);

GGTYSCFGPLTWVCKPQGG (SEQ ID NO;

21); and

,

YCHFGPLTWVC (SEQ ID NO;

17).

2. The method of claim 1, wherein each of said monomeric peptides is independently selected from:

GGTASCHFGPLTWVCKPQGG (SEQ ID NO

     19);

GGTYSCHFAPLTWVCKPQGG (SEQ ID NO;

20);

GGTYSCFGPLTWVCKPQGG (SEQ ID NO;

21);

YCHFGPLTWVC (SEQ ID NO;

17).

3. The method of claim 1, wherein the cell culture comprises cortical cells.

4. The method of claim 1, wherein the cell culture comprises hippocampal cells.